

## **Pharmacy Drug Policy Checklist**

POLICY NAME Livtencity (marivabir) POLICY # 3100P

## Criteria

Coverage Criteria	
	Diagnosis of post-transplant CMV infection/disease with a history of hematopoietic stem cell transplant or solid organ transplant
	Age 12 years or older and weighs at least 35 kg
	Prescribed by transplant surgeon, infectious disease specialist, or oncologist
	Documented trial and failure of at least one of the following: ganciclovir, valganciclovir, foscarnet, or cidofovir
Exclusion Criteria – Any of the following prevents coverage	
	Livtencity will not be approved concurrently with any other CMV antivirals